• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up2.00% Nasdaq Up1.66%

    Organovo Holdings, Inc. (ONVO)

    1.89 Down 0.04(2.07%) Feb 12, 4:02PM EST
    |After Hours : 1.81 Down 0.08 (4.23%) Feb 12, 4:56PM EST
    ProfileGet Profile for:
    Organovo Holdings, Inc.
    6275 Nancy Ridge Drive
    Suite 110
    San Diego, CA 92121
    United States - Map
    Phone: 858-224-1000
    Website: http://www.organovo.com

    Index Membership:N/A
    Industry:Medical Laboratories & Research
    Full Time Employees:80

    Business Summary 

    Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. It is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair, and functional tissue patches for the repair or replacement of damaged tissues and organs. The company has a collaboration agreement with Merck Sharp & Dohme Corp. (Merck). that provides Merck access to the company’s commercial exVive3D human liver tissue service, as well as to develop multiple custom tissue models. Organovo Holdings, Inc. was founded in 2007 and is based in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Organovo Holdings, Inc.

    Corporate Governance 
    Organovo Holdings, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Keith Murphy , 44
    Chairman, Chief Exec. Officer, Pres, Member of Audit Committee and Member of Science & Technology Committee
    Mr. Barry D. Michaels , 66
    Chief Financial Officer
    Dr. Sharon Collins Presnell Ph.D., 47
    Chief Technology Officer and Exec. VP of R&D
    Ms. Jennifer Kinsbruner Bush J.D., 41
    Compliance Officer, Gen. Counsel and Corp. Sec.
    Dr. Eric Michael David M.D., J.D., Ph.D., 44
    Chief Strategy Officer and Exec. VP of Pre-Clinical Devel.
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders